Xin Lang Cai Jing·2025-10-30 01:57Core Viewpoint - Junshi Bioscience's stock price has shown a year-to-date increase of 39.70%, but has experienced fluctuations in the short term, including a recent decline of 2.00% on October 30, 2023 [1][2]. Company Overview - Junshi Bioscience, established on December 27, 2012, and listed on July 15, 2020, is located in Shanghai and focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [2]. - The company's main revenue sources are drug sales (90.67%), technology licensing and royalties (8.74%), and technical services and others (0.59%) [2]. Financial Performance - For the period from January to September 2025, Junshi Bioscience reported a revenue of 1.806 billion yuan, representing a year-on-year growth of 42.06%. However, the net profit attributable to shareholders was -596 million yuan, reflecting a year-on-year increase of 35.72% in losses [2]. Stock Performance and Trading Activity - As of October 30, 2023, Junshi Bioscience's stock was trading at 38.18 yuan per share, with a market capitalization of 39.199 billion yuan. The stock has seen a trading volume of 73.1565 million yuan and a turnover rate of 0.25% [1]. - The stock has experienced a recent net outflow of 6.2523 million yuan in principal funds, with significant selling pressure observed [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Junshi Bioscience increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by major ETFs [3].